Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Stock Has Consensus Target Price of $5.88 According to Analysts

Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $5.88.

Several analysts have recently issued reports on the stock. Leerink Partners initiated coverage on shares of Connect Biopharma in a research report on Monday, October 12th. They set an “outperform” rating and a $4.00 target price on the stock. Wall Street Zen lowered Connect Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Oppenheimer dropped their price target on Connect Biopharma to $5.00 and set an “outperform” rating for the company in a research report on Tuesday, September 22nd. HC Wainwright reissued a “buy” rating on shares of Connect Biopharma in a research note on Wednesday, October 28th. Finally, Weiss Ratings downgraded Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st.

View Our Latest Stock Report on CNTB

Hedge Funds Weigh In On Connect Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE purchased a new position in Connect Biopharma during the first quarter worth $41,000. Marshall Wace LLP increased its position in Connect Biopharma by 12.0% during the third quarter. Marshall Wace LLP now owns 376,029 shares of the company’s stock valued at $414,000 after acquiring an additional 40,387 shares during the last quarter. Knott David M Jr increased its position in Connect Biopharma by 93.9% during the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock valued at $1,016,000 after acquiring an additional 187,835 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in Connect Biopharma during the first quarter valued at $1,945,000. Finally, BML Capital Management LLC raised its stake in shares of Connect Biopharma by 574.1% in the third quarter. BML Capital Management LLC now owns 3,864,400 shares of the company’s stock valued at $4,251,000 after acquiring an additional 3,291,113 shares during the period. Hedge funds and other institutional investors own 58.72% of the company’s stock.

Connect Biopharma Stock Performance

Shares of NASDAQ:CNTB opened at $0.68 on Monday. The firm has a fifty day simple moving average of $1.04 and a two-hundred day simple moving average of $2.11. Connect Biopharma has a 52 week low of $0.64 and a 52 week high of $3.82. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $42.65 million, a P/E ratio of -0.57 and a beta of 0.06.

About Connect Biopharma

(Get Free Report)

Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.

Further Reading

Analyst Recommendations for Connect Biopharma (NASDAQ:CNTB)

Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.